BioNTech SE (BNTX)
| Previous close | 161.03 |
| Open | 157.06 |
| Bid | 156.78 x 1000 |
| Ask | 156.91 x 900 |
| Day's range | 155.31 - 159.67 |
| 52-week range | 117.08 - 464.00 |
| Volume | |
| Avg. volume | 1,283,976 |
| Market cap | 38.255B |
| Beta (5Y monthly) | -0.70 |
| PE ratio (TTM) | 5.00 |
| EPS (TTM) | 31.54 |
| Earnings date | 09 Nov 2021 |
| Forward dividend & yield | 2.11 (1.33%) |
| Ex-dividend date | 02 Jun 2022 |
| 1y target est | 320.42 |
- Motley Fool
This May Be Pfizer's Key to Long-Term Vaccine Dominance
Pfizer (NYSE: PFE) is already the leader in the coronavirus vaccine space. Rival Moderna (NASDAQ: MRNA) has a significant position in the market. Latecomer Novavax (NASDAQ: NVAX) could also take market share in the months to come.
- The Telegraph
German drugmaker accused of stealing Covid vaccine technology
The team behind Britain’s most-used Covid booster vaccine is being sued by a German pharmaceutical firm which has accused it of stealing the technology behind the jab.
- Reuters
CureVac files patent lawsuit in Germany against BioNTech over mRNA technology
BERLIN (Reuters) -CureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce competition to develop a vaccine against the coronavirus. The German-based biotech company is seeking "fair compensation" from BioNTech and two subsidiaries for infringement of its intellectual property rights, it said on Tuesday. When asked in a media call, Chief Executive Franz-Werner Haas did not rule out further legal action against BioNTech partner Pfizer or mRNA vaccine maker Moderna.
